429 related articles for article (PubMed ID: 16548447)
1. The yin and yang of tumor necrosis factor inhibitors.
Calabrese L
Cleve Clin J Med; 2006 Mar; 73(3):251-6. PubMed ID: 16548447
[TBL] [Abstract][Full Text] [Related]
2. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
Gaudin P
Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
[No Abstract] [Full Text] [Related]
3. [Therapeutic efficacy and the adverse effects of newly developed biological agents for rheumatoid arthritis].
Kondo H
Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):153-60. PubMed ID: 14968591
[No Abstract] [Full Text] [Related]
4. [TNF targetting therapy for rheumatoid arthritis].
Takeuchi T
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1787-94. PubMed ID: 17037316
[No Abstract] [Full Text] [Related]
5. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
6. Which TNF inhibitor for rheumatoid arthritis?
Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
[No Abstract] [Full Text] [Related]
7. [TNF inhibitors for treatment of rheumatoid arthritis].
Otomo K; Koike T
Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2405-12. PubMed ID: 19149036
[No Abstract] [Full Text] [Related]
8. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
Asahina A; Ishii N; Tohma S
J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
[No Abstract] [Full Text] [Related]
9. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
González-Gay MA; Agudo M
Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
[No Abstract] [Full Text] [Related]
10. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
[TBL] [Abstract][Full Text] [Related]
11. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.
Flendrie M; Creemers MC; Welsing PM; den Broeder AA; van Riel PL
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii30-3. PubMed ID: 14532145
[TBL] [Abstract][Full Text] [Related]
12. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
Saad AA; Symmons DP; Noyce PR; Ashcroft DM
J Rheumatol; 2008 May; 35(5):883-90. PubMed ID: 18381787
[TBL] [Abstract][Full Text] [Related]
13. [Anti-TNF therapy in rheumatoid arthritis].
Yakeuchi T; Amano K
Nihon Rinsho Meneki Gakkai Kaishi; 2004 Feb; 27(1):7-15. PubMed ID: 15045810
[No Abstract] [Full Text] [Related]
14. TNF-alpha inhibition: the need for a tumor necrosis factor thermostat.
O'Dell JR
Mayo Clin Proc; 2001 Jun; 76(6):573-5. PubMed ID: 11393494
[No Abstract] [Full Text] [Related]
15. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis.
Titos Arcos JC; Hallal H; Robles M; Andrade RJ
Rev Esp Enferm Dig; 2012 May; 104(5):282-4. PubMed ID: 22662786
[No Abstract] [Full Text] [Related]
16. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
[TBL] [Abstract][Full Text] [Related]
17. Response to: 'Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)' by Iannone et al.
Neovius M; Askling J
Ann Rheum Dis; 2014 Jun; 73(6):e32. PubMed ID: 24638970
[No Abstract] [Full Text] [Related]
18. Tumour necrosis factor inhibitors--what we need to know.
Hasan U
N Z Med J; 2006 Dec; 119(1246):U2336. PubMed ID: 17151710
[TBL] [Abstract][Full Text] [Related]
19. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials.
Michaud TL; Rho YH; Shamliyan T; Kuntz KM; Choi HK
Am J Med; 2014 Dec; 127(12):1208-32. PubMed ID: 24950486
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors.
Anderson P; Louie J; Lau A; Broder M
Curr Rheumatol Rep; 2005 Mar; 7(1):3-9. PubMed ID: 15760575
[No Abstract] [Full Text] [Related]
[Next] [New Search]
